摘要:
The present invention relates to an agent for the prevention/therapy of a disease caused by keratinocyte growth, which comprises, as an active ingredient, a compound represented by General Formula (1):
wherein A represents a group selected from groups of the following formulas:
X represents CH or N; Y represents CH 2 or C=O; Z represents CH or N; R 1 represents an alkoxy group; R 2 and R 3 each independently represent an alkyl group; R 4 represents an alkyl group, and a group of the following formula:
R 5 each independently represent an alkoxy group or an alkylthio group; m represents an integer from 1 to 3; n represents an integer of 1 or 2; and o represents an integer of 1 or 2, or a salt thereof, or a solvate of the compound or the salt.
摘要:
A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.
摘要翻译:提供了具有对蛋白酶的抗性和毒性降低的改良的葡萄球菌肠毒素B(SEB)和包含所述修饰的SEB的疫苗。 具有如SEQ ID NO:1所示的氨基酸序列的修饰SEB,其中97位的赖氨酸和98位的赖氨酸被任何其它氨基酸或其衍生物取代,并且包含 所述经修饰的SEB或其衍生物。
摘要:
It is intended to provide a novel compound, which sustains an ACAT inhibitory activity and a macrophage-selectivity to a certain degree as a practically usable drug and can maintain an excellent oral absorption property and a favorable drug concentration in case of tested in vivo; a process for producing the same; medicinal compositions comprising the same and its intermediate. Namely, 2-[4-[2-(7-trifuoromethylbenzoxazol-2-ylthio)-ethyl]piperazin-1-yl]-N-(2,6-diisopropyl-4-hydroxyphenyl)-acetamide represented by the following formula: salts thereof or solvates of the same; and medicinal compositions comprising the compound represented by the above formula, salts thereof or solvates of the same together with pharmaceutically acceptable carriers.